Worth reading
28Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
Annual updateKey initiatives
01Focus on areas where CRISPR-GNDM® can deliver the greatest value
02Focus development on neuromuscular diseases, centered on MDL-101
03Preparations for clinical development are progressing
04Mouse IND-enabling studies
05GLP toxicity studies in monkeys
06GMP manufacturing
07Preparation of clinical sites
08Innovation in muscle-selective capsids enables optimization of efficacy, safety and cost
Non-financial targetsIndicator IND filing / Target value Late 2026 to early 2027 / Timing Late 2026 to early 2027, Indicator Start of FIH trial and clinical trials in the United States / Target value First half of 2027 / Timing First half of 2027
Size of the Target MarketSubject Rare diseases overall / Scale Unmet patient needs affecting approximately 400 million people / Growth rate Not disclosed / Source Evaluate Pharma and Citi Research (January 2024), among others, Subject LAMA2-RD / Scale More than $500M / Growth rate Not disclosed / Source Not disclosed, Subject DMD / Scale US$4.1 billion in 2026 to US$9.6 billion in 2031 / Growth rate CAGR of 18.8%. The main text also states a CAGR of 42.5% / Source Mordor Intelligence, 2026, Subject DM1 and DM2 / Scale $2.2B (2032 forecast) / Growth rate Not disclosed / Source DelveInsight (covering both DM1 and DM2), Subject In vivo gene therapy market by product / Scale Luxturna $65 million, Zolgensma approximately $1 billion, HEMGENIX $3.2 billion, Vyjuvek approximately $200 million, Roctavian $11 billion, beqvez $3.2 billion, ELEVIDYS $4.1 billion, Itvisma approximately $10 billion, Otarmeni $130 million / Growth rate Not disclosed / Source National Organization for Rare Disorders, Fierce Biotech, company websites, Grand View Research, Fortune Business Insights, Mordor Intelligence, 2026
Risks identified by the company
Ability to deliver sufficient quantities throughout the body's muscles, with high efficiency and broad distribution
Stability of long-term expression following a single dose, providing sustained efficacy
Design that ensures safety even at high doses, including immune and inflammation management
Framework for appropriately measuring and evaluating efficacy, including biomarkers and assessment endpoints
Management of inflammation and immune responses associated with high doses
Competition is intensifying, including from new entrants
| Item | Details |
|---|---|
| Plan name | Business Plan and Growth Potential |
| Progress against the plan | Annual update |
| Non-financial targets | Indicator IND filing / Target value Late 2026 to early 2027 / Timing Late 2026 to early 2027, Indicator Start of FIH trial and clinical trials in the United States / Target value First half of 2027 / Timing First half of 2027 |
| Key initiatives | Focus on areas where CRISPR-GNDM® can deliver the greatest value, Focus development on neuromuscular diseases, centered on MDL-101, Preparations for clinical development are progressing, Mouse IND-enabling studies, GLP toxicity studies in monkeys, GMP manufacturing, Preparation of clinical sites, Innovation in muscle-selective capsids enables optimization of efficacy, safety and cost |
| Size of the Target Market | Subject Rare diseases overall / Scale Unmet patient needs affecting approximately 400 million people / Growth rate Not disclosed / Source Evaluate Pharma and Citi Research (January 2024), among others, Subject LAMA2-RD / Scale More than $500M / Growth rate Not disclosed / Source Not disclosed, Subject DMD / Scale US$4.1 billion in 2026 to US$9.6 billion in 2031 / Growth rate CAGR of 18.8%. The main text also states a CAGR of 42.5% / Source Mordor Intelligence, 2026, Subject DM1 and DM2 / Scale $2.2B (2032 forecast) / Growth rate Not disclosed / Source DelveInsight (covering both DM1 and DM2), Subject In vivo gene therapy market by product / Scale Luxturna $65 million, Zolgensma approximately $1 billion, HEMGENIX $3.2 billion, Vyjuvek approximately $200 million, Roctavian $11 billion, beqvez $3.2 billion, ELEVIDYS $4.1 billion, Itvisma approximately $10 billion, Otarmeni $130 million / Growth rate Not disclosed / Source National Organization for Rare Disorders, Fierce Biotech, company websites, Grand View Research, Fortune Business Insights, Mordor Intelligence, 2026 |
| Risks identified | Ability to deliver sufficient quantities throughout the body's muscles, with high efficiency and broad distribution, Stability of long-term expression following a single dose, providing sustained efficacy, Design that ensures safety even at high doses, including immune and inflammation management, Framework for appropriately measuring and evaluating efficacy, including biomarkers and assessment endpoints, Management of inflammation and immune responses associated with high doses, Competition is intensifying, including from new entrants |
| Publication date | 14 July 2026 |
Items this document does not state (18)
Plan periodSales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetPlan assumptionsResults under the previous planReason for revision or withdrawalDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company states that it aims to ensure safety and efficacy through robust nonclinical data and systematic execution, with the goal of entering clinical development at an early stage.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.